Latest Hodgkin's lymphoma Stories
Community Leaders throughout the North Bay Area Assemble to Join LLS in the Fight against Blood Cancers SANTA ROSA, Calif., April 8, 2014 /PRNewswire-USNewswire/ -- The Leukemia &
Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc.
New Program Brings Busy Moms Together to Get In Shape, Meet Other Moms and Raise Funds to Help Fight Cancer SAN FRANCISCO, April 2, 2014 /PRNewswire-USNewswire/ -- The Leukemia &
WHITE PLAINS, N.Y., March 31, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced that its Canadian affiliate, The Leukemia & Lymphoma Society of Canada (LLSC), has
MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh,
Scientists say patients with certain forms of aggressive Non-Hodgkin’s Lymphoma are more likely to survive if they respond well to their first treatment. Raleigh,
- A transitional zone between two communities containing the characteristic species of each.